JCJordan S. F. Chan

Jordan S. F. Chan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jordan S. F. Chan has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • John Reyes Ussher

    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada

    5 shared publications
  • Christina T. Saed

    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada

    2 shared publications
  • Farah Eaton

    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB Canada; Alberta Diabetes Institute, University of Alberta, Edmonton, AB Canada; Cardiovascular Research Institute, University of Alberta, Edmonton, AB Canada; Women and Children's Health Research Institute, University of Alberta, Edmonton, AB Canada

    2 shared publications
  • Kunyan Yang

    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada

    2 shared publications
  • Linyue Dong

    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB Canada; Alberta Diabetes Institute, University of Alberta, Edmonton, AB Canada; Cardiovascular Research Institute, University of Alberta, Edmonton, AB Canada; Women and Children's Health Research Institute, University of Alberta, Edmonton, AB Canada; School of Pharmacy, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai, 201203, China

    2 shared publications
  • Seyed Amirhossein Tabatabaei Dakhili

    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB Canada; Alberta Diabetes Institute, University of Alberta, Edmonton, AB Canada; Cardiovascular Research Institute, University of Alberta, Edmonton, AB Canada; Women and Children's Health Research Institute, University of Alberta, Edmonton, AB Canada

    2 shared publications

Latest Publications

  • Open Access

    Ovariectomy abolishes cardioprotection against diastolic dysfunction and impairs cardiac glucose oxidation in female mice with type 2 diabetes

    by Jordan S.F. Chan, Christina T. Saed, Raven Kirschenman, Cory S. Wagg, Alexa N. King, M.TOni E. Dimaano, Faina Benyaminov, Amanda A. Greenwell, Linyue Dong, Kunyan Yang, et al.

  • Metabolic modulation of pyruvate dehydrogenase and glucose oxidation in diabetic cardiomyopathy: pathways, perspectives, and potentials

    by Jordan S. F. Chan, Linyue Dong, John R. Ussher

    Individuals living with obesity and/or type 2 diabetes (T2D) are at a disproportionately high risk of developing cardiovascular disease. This includes diabetic cardiomyopathy (DbCM), a condition characterized by left ventricular diastolic dysfunction that is often present in individuals with pre- or early-stage T2D. Although there are numerous mediators that contribute to the development of DbCM, perturbations in cardiac substrate metabolism are widely believed to play a major role in its pathogenesis. In particular, myocardial glucose oxidation is often suppressed due to decreased activity of the pyruvate dehydrogenase (PDH) complex, the rate-limiting enzyme of glucose oxidation, which is responsible for decarboxylating pyruvate to acetyl CoA, thus acting as the link between glycolysis and oxidative phosphorylation of glucose. Importantly, numerous preclinical studies suggest that restoring suppressed myocardial glucose oxidation can alleviate DbCM. In this review, we will describe the major perturbations that characterize myocardial substrate metabolism in T2D, while discussing the primary pharmacological approaches that have been pursued to stimulate myocardial PDH activity and glucose oxidation. We will also highlight potential mechanisms explaining how increasing myocardial PDH activity and glucose oxidation favorably influence diastolic function. Given the increasing prevalence of DbCM in the human population, it is not only imperative to better understand its pathophysiology but also to develop novel therapies for its management, which may also have utility in the management of heart failure with preserved ejection fraction.


  • Open Access

    Cardiac substrate metabolism in type 2 diabetes

    by Jordan S. F. Chan, Tanin Shafaati, John R. Ussher

    As the most metabolically demanding organ on a per gram basis, substrate metabolism in the heart is intricately linked to cardiac function. Virtually all major cardiovascular pathologies are associated with perturbations in cardiac substrate metabolism, and increasing evidence supports that these perturbations in substrate metabolism can directly contribute to cardiac dysfunction. Furthermore, type 2 diabetes (T2D) is a major risk factor for increased cardiovascular disease burden, while also being characterized by a very distinct metabolic profile in the heart. This includes increases in cardiac fatty oxidation rates and a robust reduction in cardiac glucose oxidation rates. Herein, we will describe the primary mechanisms responsible for the increase in cardiac fatty acid oxidation and decrease in cardiac glucose oxidation during T2D, while also detailing perturbations in cardiac ketone and amino acid metabolism. In addition, we will interrogate preclinical studies that have addressed whether correcting perturbations in cardiac substrate metabolism may have clinical utility against ischemic heart disease, diabetic cardiomyopathy, or heart failure associated with T2D. Lastly, we will consider the translational potential of such an approach to manage cardiovascular disease in people living with T2D.


  • Incretin-mediated control of cardiac energy metabolism

    by Jordan S F Chan, Tanin Shafaati, John R Ussher

    Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like-peptide-1 (GLP-1) are incretin hormones that stimulate insulin secretion and improve glycemic control in individuals with type 2 diabetes (T2D). Data from several cardiovascular outcome trials for GLP-1 receptor (GLP-1R) agonists have demonstrated significant reductions in the occurrence of major adverse cardiovascular events in individuals with T2D. Although the cardiovascular actions attributed to GLP-1R agonism have been extensively studied, little is known regarding the cardiovascular consequences attributed to GIP receptor (GIPR) agonism. As there is now an increasing focus on the development of incretin-based co-agonist therapies that activate both the GLP-1R and GIPR, it is imperative that we understand the mechanism(s) through which these incretins impact cardiovascular function. This is especially important considering that cardiovascular disease represents the leading cause of death in individuals with T2D. With increasing evidence that perturbations in cardiac energy metabolism are a major contributor to the pathology of diabetes-related cardiovascular disease, this may represent a key component through which GLP-1R and GIPR agonism influence cardiovascular outcomes. Not only do GIP and GLP-1 increase the secretion of insulin, they may also modify glucagon secretion, both of which have potent actions on cardiac substrate utilization. Herein we will discuss the potential direct and indirect actions through which GLP-1R and GIPR agonism impact cardiac energy metabolism while interrogating the evidence to support whether such actions may account for incretin-mediated cardioprotection in T2D.


  • Open Access

    Pharmacological Inhibition of Succinyl Coenzyme A:3‐Ketoacid Coenzyme A Transferase Alleviates the Progression of Diabetic Cardiomyopathy

    by Amanda A. Greenwell, Seyed Amirhossein Tabatabaei Dakhili, Cory S. Wagg, Christina T. Saed, Jordan S.F. Chan, Kunyan Yang, Indiresh A. Mangra‐Bala, Magnus J. Stenlund, Farah Eaton, Keshav Gopal, et al.